 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does CAPTOPRIL increase the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes CAPTOPRIL increase the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes CAPTOPRIL increase the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does CAPTOPRIL increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"CAPTOPRIL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: CAPTOPRIL: indications_and_usage: INDICATIONS & USAGE Captopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. The blood pressure lowering effects of [0m
[31mcaptopril and thiazides are approximately additive. This fixed combination drug may be used as initial therapy or substituted for previously titrated doses of the individual components. When captopril[0m
[31mand hydrochlorothiazide are given together it may not be necessary to administer captopril in divided doses to attain blood pressure control at trough [0m[1;31m([0m[31mbefore the next dose[0m[1;31m)[0m[31m. Also, with such a [0m
[31mcombination, a daily dose of [0m[1;31m15[0m[31m mg of hydrochlorothiazide may be adequate. Treatment may, therefore, be initiated with captopril and hydrochlorothiazide tablets [0m[1;31m25[0m[31m mg/[0m[1;31m15[0m[31m mg once daily. CAPTOPRIL: [0m
[31mindications_and_usage: Subsequent titration should be with additional doses of the components [0m[1;31m([0m[31mcaptopril, hydrochlorothiazide[0m[1;31m)[0m[31m as single agents or as captopril and hydrochlorothiazide tablets [0m[1;31m50[0m[31m mg/[0m[1;31m15[0m
[31mmg, [0m[1;31m25[0m[31m mg/[0m[1;31m25[0m[31m mg, or [0m[1;31m50[0m[31m mg/[0m[1;31m25[0m[31m mg [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. In using captopril and hydrochlorothiazide, consideration should be given to the risk of neutropenia/agranulocytosis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mCaptopril and hydrochlorothiazide may be used for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen [0m
[31mvascular disease, captopril and hydrochlorothiazide should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to[0m
[31mother drug combinations. CAPTOPRIL: indications_and_usage: ACE inhibitors [0m[1;31m([0m[31mfor which adequate data are available[0m[1;31m)[0m[31m cause a higher rate of angioedema in black than in non-black patients [0m[1;31m([0m[31msee WARNINGS: [0m
[31mCaptopril: Head and Neck Angioedema and Intestinal Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: warnings: WARNINGS Captopril : Anaphylactoid and Possible Related Reactions : Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and [0m
[31mpolypeptides, including endogenous bradykinin, patients receiving ACE inhibitors [0m[1;31m([0m[31mincluding captopril[0m[1;31m)[0m[31m may be subject to a variety of adverse reactions, some of them serious. Head and Neck Angioedema [0m
[31m: Angioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been seen in patients treated with ACE inhibitors, including captopril. If angioedema involves the [0m
[31mtongue, glottis or larynx, airway obstruction may occur and be fatal. Emergency therapy, including but not necessarily limited to, subcutaneous administration of a [0m[1;31m1:1000[0m[31m solution of epinephrine [0m
[31mshould be promptly instituted. CAPTOPRIL: warnings: Swelling confined to the face, mucous membranes of the mouth, lips and extremities has usually resolved with discontinuation of treatment; some [0m
[31mcases required medical therapy. [0m[1;31m([0m[31mSee PRECAUTIONS: Information for Patients and ADVERSE REACTIONS: Captopril .[0m[1;31m)[0m[31m Intestinal Angioedema : Intestinal angioedema has been reported in patients treated with [0m
[31mACE inhibitors. These patients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C-[0m[1;31m1[0m[31m esterase levels were normal. [0m
[31mThe angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in[0m
[31mthe differential diagnosis of patients on ACE inhibitors presenting with abdominal pain. CAPTOPRIL: warnings: Anaphylactoid Reactions During Desensitization : Two patients undergoing desensitizing [0m
[31mtreatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were [0m
[31mtemporarily withheld, but they reappeared upon inadvertent rechallenge. Anaphylactoid Reactions During Membrane Exposure : Anaphylactoid reactions have been reported in patients dialyzed with [0m
[31mhigh-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate [0m
[31mabsorption. Neutropenia/Agranulocytosis : Neutropenia [0m[1;31m([0m[31m< [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m with myeloid hypoplasia has resulted from use of captopril. CAPTOPRIL: warnings: About half of the neutropenic patients developed [0m
[31msystemic or oral cavity infections or other features of the syndrome of agranulocytosis. The risk of neutropenia is dependent on the clinical status of the patient: In clinical trials in patients with[0m
[31mhypertension who have normal renal function [0m[1;31m([0m[31mserum creatinine less than [0m[1;31m1.6[0m[31m mg/dL and no collagen vascular disease[0m[1;31m)[0m[31m, neutropenia has been seen in one patient out of over [0m[1;31m8[0m[31m,[0m[1;31m600[0m[31m exposed. In patients [0m
[31mwith some degree of renal failure [0m[1;31m([0m[31mserum creatinine at least [0m[1;31m1.6[0m[31m mg/dL[0m[1;31m)[0m[31m but no collagen vascular disease, the risk of neutropenia in clinical trials was about [0m[1;31m1[0m[31m per [0m[1;31m500[0m[31m, a frequency over [0m[1;31m15[0m[31m times that[0m
[31mfor uncomplicated hypertension. Daily doses of captopril were relatively high in these patients, particularly in view of their diminished renal function. CAPTOPRIL: warnings: In foreign marketing [0m
[31mexperience in patients with renal failure, use of allopurinol concomitantly with captopril has been associated with neutropenia but this association has not appeared in U.S. reports. In patients with [0m
[31mcollagen vascular diseases [0m[1;31m([0m[31me.g., systemic lupus erythematosus, scleroderma[0m[1;31m)[0m[31m and impaired renal function, neutropenia occurred in [0m[1;31m3.7[0m[31m percent of patients in clinical trials. While none of the over [0m[1;31m750[0m
[31mpatients in formal clinical trials of heart failure developed neutropenia, it has occurred during the subsequent clinical experience. About half of the reported cases had serum creatinine â‰¥ [0m[1;31m1.6[0m[31m mg/dL [0m
[31mand more than [0m[1;31m75[0m[31m percent were in patients also receiving procainamide. In heart failure, it appears that the same risk factors for neutropenia are present. The neutropenia has usually been detected [0m
[31mwithin three months after captopril was started.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: adverse_reactions: ADVERSE REACTIONS Captopril : Reported incidences are based on clinical trials involving approximately [0m[1;31m7000[0m[31m patients. Renal : About one of [0m[1;31m100[0m[31m patients developed[0m
[31mproteinuria [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Each of the following has been reported in approximately [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m of [0m[1;31m1000[0m[31m patients and are of uncertain relationship to drug use: renal insufficiency, renal failure, [0m
[31mnephrotic syndrome, polyuria, oliguria, and urinary frequency. Hematologic : Neutropenia/agranulocytosis has occurred [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Cases of anemia, thrombocytopenia, and pancytopenia have been [0m
[31mreported. Dermatologic : Rash, often with pruritus, and sometimes with fever, arthralgia, and eosinophilia, occurred in about [0m[1;31m4[0m[31m to [0m[1;31m7[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients, usually [0m
[31mduring the first four weeks of therapy. CAPTOPRIL: adverse_reactions: It is usually maculopapular, and rarely urticarial. The rash is usually mild and disappears within a few days of dosage reduction,[0m
[31mshort-term treatment with an antihistaminic agent, and/or discontinuing therapy; remission may occur even if captopril is continued. Pruritus, without rash, occurs in about [0m[1;31m2[0m[31m of [0m[1;31m100[0m[31m patients. Between [0m
[1;31m7[0m[31m and [0m[1;31m10[0m[31m percent of patients with skin rash have shown eosinophilia and/or positive ANA titers. A reversible associated pemphigoid-like lesion, and photosensitivity, have also been reported. Flushing [0m
[31mor pallor has been reported in [0m[1;31m2[0m[31m to [0m[1;31m5[0m[31m of [0m[1;31m1000[0m[31m patients. Cardiovascular : Hypotension may occur; see WARNINGS and PRECAUTIONS [0m[1;31m([0m[31mDrug Interactions[0m[1;31m)[0m[31m for discussion of hypotension with captopril therapy. [0m
[31mTachycardia, chest pain, and palpitations have each been observed in approximately [0m[1;31m1[0m[31m of [0m[1;31m100[0m[31m patients. CAPTOPRIL: adverse_reactions: Angina pectoris, myocardial infarction, Raynaudâ€™s syndrome, and [0m
[31mcongestive heart failure have each occurred in [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m of [0m[1;31m1000[0m[31m patients. Dysgeusia : Approximately [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m [0m[1;31m([0m[31mdepending on renal status and dose[0m[1;31m)[0m[31m of [0m[1;31m100[0m[31m patients developed a diminution or loss of taste [0m
[31mperception. Taste impairment is reversible and usually self-limited [0m[1;31m([0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m months[0m[1;31m)[0m[31m even with continued drug administration. Weight loss may be associated with the loss of taste. Angioedema : [0m
[31mAngioedema involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been reported in approximately one in [0m[1;31m1000[0m[31m patients. Angioedema involving the upper airways has caused[0m
[31mfatal airway obstruction. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Head and Neck Angioedema and Intestinal Angioedema and PRECAUTIONS: Information for Patients [0m[1;31m)[0m[31m. CAPTOPRIL: adverse_reactions: Cough : Cough has been[0m
[31mreported in [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m% of patients treated with captopril in clinical trials [0m[1;31m([0m[31msee PRECAUTIONS: General: Captopril: Cough [0m[1;31m)[0m[31m. The following have been reported in about [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m percent of patients but [0m
[31mdid not appear at increased frequency compared to placebo or other treatments used in controlled trials: gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, [0m
[31maphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, alopecia, paresthesias. Other clinical adverse effects reported since the drug was marketed are [0m
[31mlisted below by body system. In this setting, an incidence or causal relationship cannot be accurately determined. CAPTOPRIL: adverse_reactions: Body as a Whole : Anaphylactoid reactions [0m[1;31m([0m[31msee [0m
[31mWARNINGS: Captopril: Anaphylactoid and Possibly Related Reactions and PRECAUTIONS: Hemodialysis [0m[1;31m)[0m[31m. General : asthenia, gynecomastia. Cardiovascular : cardiac arrest, cerebrovascular [0m
[31maccident/insufficiency, rhythm disturbances, orthostatic hypotension, syncope. Dermatologic : bullous pemphigus, erythema multiforme [0m[1;31m([0m[31mincluding Stevens-Johnson syndrome[0m[1;31m)[0m[31m, exfoliative dermatitis. [0m
[31mGastrointestinal : pancreatitis, glossitis, dyspepsia. Hematologic : anemia, including aplastic and hemolytic. Hepatobiliary : jaundice, hepatitis, including rare cases of necrosis, cholestasis. [0m
[31mMetabolic : symptomatic hyponatremia. Musculoskeletal : myalgia, myasthenia.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m


[31mCONTENT: CAPTOPRIL: information_for_patients: INFORMATION FOR PATIENTS Patients should be advised to immediately report to their physician any signs or symptoms suggesting angioedema [0m[1;31m([0m[31me.g., swelling [0m
[31mof face, eyes, lips, tongue, larynx and extremities; difficulty in swallowing or breathing; hoarseness[0m[1;31m)[0m[31m and to discontinue therapy. [0m[1;31m([0m[31mSee WARNINGS: Captopril: Head and Neck Angioedema and Intestinal [0m
[31mAngioedema .[0m[1;31m)[0m[31m Patients should be told to report promptly any indication of infection [0m[1;31m([0m[31me.g., sore throat, fever[0m[1;31m)[0m[31m, which may be a sign of neutropenia, or of progressive edema which might be related to [0m
[31mproteinuria and nephrotic syndrome. All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. [0m
[31mOther causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician. CAPTOPRIL: information_for_patients: [0m
[31mPatients should be advised not to use potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes without consulting their physician. [0m[1;31m([0m[31mSee PRECAUTIONS: General and Drug[0m
[31mInteractions: Captopril ; ADVERSE REACTIONS: Captopril .[0m[1;31m)[0m[31m Patients should be warned against interruption or discontinuation of medication unless instructed by the physician. Heart failure patients on [0m
[31mcaptopril therapy should be cautioned against rapid increases in physical activity. Patients should be informed that captopril and hydrochlorothiazide tablets should be taken one hour before meals [0m
[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:CA[0m[31mPTOPRIL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Yes, CAPTOPRIL does increase the risk of angioedema. Angioedema involving the extremities, face, lips, mucous membranes, tongue, glottis, or larynx has been reported in approximately one in [0m
[1;32m1000[0m[32m patients. Angioedema involving the upper airways has caused fatal airway obstruction in some cases. The risk of angioedema is higher in black patients compared to non-black patients.[0m

[32mSOURCE: CAPTOPRIL label[0m
[32mEXTRACT_START_END: ACE inhibitors [0m[1;32m([0m[32mfor which[0m[32m...[0m[32mIntestinal Angioedema[0m[1;32m)[0m[32m.[0m
*[1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Yes, CAPTOPRIL does increase the risk of angioedema. Angioedema [0m
[34minvolving the extremities, face, lips, mucous membranes, tongue, glottis, or larynx has been reported in approximately one in [0m[1;34m1000[0m[34m patients. Angioedema involving the upper airways has caused fatal [0m
[34mairway obstruction in some cases. The risk of angioedema is higher in black patients compared to non-black patients.[0m

[34mSOURCE: CAPTOPRIL label[0m
[34mEXTRACT_START_END: ACE inhibitors [0m[1;34m([0m[34mfor which[0m[34m...[0m[34mIntestinal Angioedema[0m[1;34m)[0m[34m.[0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does CAPTOPRIL increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if CAPTOPRIL increases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler confirmed that CAPTOPRIL does increase the risk of angioedema, with reports of angioedema in approximately one in 1000 patients. Angioedema can involve various parts of the body [0m
[32mincluding extremities, face, lips, mucous membranes, tongue, glottis, or larynx. Fatal airway obstruction has occurred in some cases, and the risk is higher in black patients compared to non-black [0m
[32mpatients."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"CAPTOPRIL increases the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does CAPTOPRIL increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if CAPTOPRIL increases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler confirmed that CAPTOPRIL does increase the risk of angioedema, with reports of angioedema in approximately one in 1000 patients. Angioedema can involve various parts of the body [0m
[34mincluding extremities, face, lips, mucous membranes, tongue, glottis, or larynx. Fatal airway obstruction has occurred in some cases, and the risk is higher in black patients compared to non-black [0m
[34mpatients."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"CAPTOPRIL increases the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does CAPTOPRIL increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if CAPTOPRIL increases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler confirmed that CAPTOPRIL does increase the risk of angioedema, with reports of angioedema in approximately one in [0m[1;31m1000[0m[31m patients. Angioedema can involve various parts of the body [0m
[31mincluding extremities, face, lips, mucous membranes, tongue, glottis, or larynx. Fatal airway obstruction has occurred in some cases, and the risk is higher in black patients compared to non-black [0m
[31mpatients.[0m
[31m        -----[0m
[31m        Final answer: CAPTOPRIL increases the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-CAPTOPRIL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mCAPTOPRIL increases the risk of angioedema. This has been reported in approximately one in [0m[1;32m1000[0m[32m patients, and can involve various parts of the body including extremities, face, lips, mucous membranes,[0m
[32mtongue, glottis, or larynx. Fatal airway obstruction has occurred in some cases, and the risk is higher in black patients compared to non-black patients.[0m
